EUVIMEDEUVIMED entdecken
Crossref

Network pharmacology analysis and molecular mechanism of paeoniflorin and its metabolite in prolactinoma cells

Min Cao, Lun-Shan Xu, Ping Huang, Bin-Bin Fan, Yi-Hua Zhang

Molecular Diversity · 2025

DOI: 10.1007/s11030-024-10923-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Min Cao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Daping Hospital, Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Glucosides, Prolactinoma, Network Pharmacology, Monoterpenes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prolactinoma was the most common functional pituitary neuroendocrine tumor tissue type, which was caused by excessive proliferation of pituitary prolactin (PRL) cells. Drug therapy of dopamine receptor agonists was generally considered as the prior treatment for prolactinoma patients. However, there were still prolactinoma patients who were resistant to dopamine agonists. Studies have been reported that paeoniflorin can inhibit the secretion of PRL in prolactinoma cells lacking dopamine D2 receptor (D2R) expression, and paeoniflorin can be metabolized into albiflorin by intestinal flora in rats. The effect of albiflorin on prolactinoma has not been reported yet. In this study, network pharmacology was used to analyze the mechanism of paeoniflorin and its metabolite albiflorin as multi-target therapy for prolactinoma, and the experimental verification was carried out. In order to clarify the complex relationship among paeoniflorin, albiflorin and prolactinoma, we constructed a component-target-disease network, and further constructed interaction network, MMP9, EGFR, FGF2, FGFR1 and LGALS3 were screened as the core targets. Kyoto encyclopedia of genes and genomes (KEGG) analysis showed that paeoniflorin and albiflorin may be involved in various pathways in the treatment of prolactinoma, included relaxin signaling pathway and PI3K-Akt signaling pathway. Molecular docking analysis showed that paeoniflorin and albiflorin had good binding activity with MMP9. Western blotting results showed that paeoniflorin and albiflorin could significantly reduce the expression of MMP9, and ELISA results showed that paeoniflorin and albiflorin could significantly reduce the concentration of PRL in GH3 cells, and the reduce degree of albiflorin was stronger than paeoniflorin at 50 μM, which indicated that albiflorin might be a potential drug to treat prolactinoma, which can regulate prolactinoma through MMP9 and reduce the concentration of PRL. Our study provided a new therapeutic strategy for prolactinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesProlactinomaNetwork PharmacologyMonoterpenesPituitary NeoplasmsHumansCell Line, TumorMolecular Docking SimulationSignal TransductionAnimalsRatsProtein Interaction MapsBridged-Ring CompoundsGlycosides

Stichwörter der Autor:innen

AlbiflorinMMP9Network pharmacologyPaeoniflorinProlactinoma

Substanzen

GlucosidesMonoterpenesBridged-Ring CompoundspeoniflorinGlycosidesalbiflorin

Autor:innen und Institutionen

  • Department of Neurosurgery, Daping Hospital, Army Medical University, Chongqing, China.
  • Department of Neurosurgery, Daping Hospital, Army Medical University, Chongqing, China. zhangyihua666@tmmu.edu.cn.

Förderung

  • Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission

Zitieren

APA

Cao, M., Xu, L. S., Huang, P., Fan, B. B., & Zhang, Y. H. (2025). Network pharmacology analysis and molecular mechanism of paeoniflorin and its metabolite in prolactinoma cells. Molecular Diversity. https://doi.org/10.1007/s11030-024-10923-8

Vancouver

Cao M, Xu LS, Huang P, Fan BB, Zhang YH. Network pharmacology analysis and molecular mechanism of paeoniflorin and its metabolite in prolactinoma cells. Molecular Diversity. 2025. doi:10.1007/s11030-024-10923-8

BibTeX
@article{Cao2025,
  author = {Cao, Min and Xu, Lun-Shan and Huang, Ping and Fan, Bin-Bin and Zhang, Yi-Hua},
  title = {Network pharmacology analysis and molecular mechanism of paeoniflorin and its metabolite in prolactinoma cells},
  journal = {Molecular Diversity},
  year = {2025},
  doi = {10.1007/s11030-024-10923-8}
}
Kostenlos starten →